Creative Medical Technology Holdings Inc Total Assets
Creative Medical Technology Holdings Inc total assets. Based on the latest financial reports, Creative Medical Technology Holdings Inc (CELZ) holds total assets worth $9.38 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see CELZ stock market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Creative Medical Technology Holdings Inc (2006–2025)
Total assets of Creative Medical Technology Holdings Inc from 2006 to 2025. This chart illustrates how Creative Medical Technology Holdings Inc's total assets have evolved over time, based on quarterly financial data. See Creative Medical Technology Holdings Inc share price for real-time trading data and today's change.
Creative Medical Technology Holdings Inc - Asset Composition Analysis
Creative Medical Technology Holdings Inc Total Assets Breakdown (December 2025)
Creative Medical Technology Holdings Inc total assets breakdown as of December 2025. Creative Medical Technology Holdings Inc's total assets of $9.38 Million consist of 94.7% current assets and 5.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 92.3% |
| Accounts Receivable | $52.08K | 0.7% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $407.23K | 5.2% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2006–2025)
This chart illustrates how Creative Medical Technology Holdings Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore CELZ net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Creative Medical Technology Holdings Inc's current assets represent 94.7% of total assets in 2025, a decrease from 100.0% in 2006.
- Cash Position: Cash and equivalents constituted 92.3% of total assets in 2025, up from 0.0% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 5.0% of total assets, an increase from 0.0% in 2006.
- Asset Diversification: The largest asset category is intangible assets at 5.2% of total assets.
Creative Medical Technology Holdings Inc Competitors by Total Assets
Key competitors of Creative Medical Technology Holdings Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Hyloris Developmentsen Sa
BR:HYL
|
Belgium | €37.05 Million |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
Oruka Therapeutics, Inc.
NASDAQ:ORKA
|
USA | $1.14 Billion |
|
Gempharmatech Co. Ltd. A
SHG:688046
|
China | CN¥2.80 Billion |
|
Vor Biopharma Inc
NASDAQ:VOR
|
USA | $481.05 Million |
|
Inventiva S.A
PA:IVA
|
France | €249.51 Million |
|
Sunmax Biotechnology Co Ltd
TWO:4728
|
Taiwan | NT$1.90 Billion |
|
Apnimed, Inc. Common Stock
NASDAQ:APMD
|
USA | $342.63 Million |
Creative Medical Technology Holdings Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.91 | 23.89 | 0.74 |
| Quick Ratio | 12.73 | 23.89 | 0.74 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $8.32 Million | $6.36 Million | $-917.33K |
Creative Medical Technology Holdings Inc - Advanced Valuation Insights
This section examines the relationship between Creative Medical Technology Holdings Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.85 |
| Latest Market Cap to Assets Ratio | 0.57 |
| Asset Growth Rate (YoY) | 17.1% |
| Total Assets | $7.81 Million |
| Market Capitalization | $4.44 Million USD |
Valuation Analysis
Below Book Valuation: The market values Creative Medical Technology Holdings Inc's assets below their book value (0.57x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Creative Medical Technology Holdings Inc's assets grew by 17.1% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Creative Medical Technology Holdings Inc (2006–2025)
The table below shows the annual total assets of Creative Medical Technology Holdings Inc from 2006 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $7.81 Million | +17.10% |
| 2024-12-31 | $6.67 Million | -37.76% |
| 2023-12-31 | $10.72 Million | -44.15% |
| 2022-12-31 | $19.19 Million | +70.27% |
| 2021-12-31 | $11.27 Million | +1469.88% |
| 2020-12-31 | $717.77K | +35.22% |
| 2019-12-31 | $530.80K | +11.24% |
| 2018-12-31 | $477.16K | +134.88% |
| 2017-12-31 | $203.15K | -37.01% |
| 2016-12-31 | $322.51K | +149211.11% |
| 2015-12-31 | $216.00 | -77.36% |
| 2014-12-31 | $954.00 | +155.08% |
| 2013-12-31 | $374.00 | -76.15% |
| 2012-12-31 | $1.57K | -49.50% |
| 2011-12-31 | $3.10K | +650.00% |
| 2010-12-31 | $414.00 | -86.54% |
| 2009-12-31 | $3.08K | +104.73% |
| 2008-12-31 | $1.50K | -95.78% |
| 2007-12-31 | $35.63K | +21.45% |
| 2006-12-31 | $29.34K | -- |
About Creative Medical Technology Holdings Inc
Creative Medical Technology Holdings, Inc., a commercial-stage biotechnology company, focuses on novel biological therapeutics in the fields of immunotherapy, endocrinology, urology, neurology, and orthopedics in the United States. The company offers CaverStem to treat erectile dysfunction, and FemCelz for the treatment of loss of genital sensitivity and dryness. It develops AlloStem (CELZ-201-DD… Read more